Skip to main content
Premium Trial:

Request an Annual Quote

Eisai London Research Labs Licenses OriGene s FlagArray cDNA Plasmids

NEW YORK, Aug. 2 (GenomeWeb News) - Eisai London Research Laboratories has licensed OriGene's FlagArray full-length cDNA plasmids, OriGene said today.

 

Eisai will use the clones, expression-ready arrays of full-length cDNA plasmids, for high-throughput drug-target discovery.

 

Eisai London is a research-based drug discovery laboratory located near UniversityCollege, London. It was established in 1990 by its parent company, Eisai of Japan.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.